Highly Effective Therapy Versus Escalation Approaches in Early Multiple Sclerosis
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Highly Effective Therapy Versus Escalation Approaches in Early Multiple Sclerosis
Authors
Keywords
-
Journal
NEUROLOGIC CLINICS
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2023-08-21
DOI
10.1016/j.ncl.2023.06.004
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Reproductive issues and multiple sclerosis: 20 questions
- (2023) Alise K. Carlson et al. CLEVELAND CLINIC JOURNAL OF MEDICINE
- Evolution of Disease Modifying Therapy Benefits and Risks: An Argument for De-escalation as a Treatment Paradigm for Patients With Multiple Sclerosis
- (2022) Brandi L. Vollmer et al. Frontiers in Neurology
- Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study
- (2022) Pascal Benkert et al. LANCET NEUROLOGY
- Therapeutic Advances in Multiple Sclerosis
- (2022) Jennifer H. Yang et al. Frontiers in Neurology
- Predictors of Disease Activity and Worsening in Relapsing-Remitting Multiple Sclerosis
- (2022) Yinan Zhang et al. Neurology-Clinical Practice
- Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis
- (2022) Lawrence Steinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Association of NEDA-4 With No Long-term Disability Progression in Multiple Sclerosis and Comparison With NEDA-3
- (2022) Dalia Rotstein et al. Neurology-Neuroimmunology & Neuroinflammation
- Updates and advances in multiple sclerosis neurotherapeutics
- (2022) Moein Amin et al. Neurodegenerative Disease Management
- Dimethyl Fumarate Delays Multiple Sclerosis in Radiologically Isolated Syndrome
- (2022) Darin T. Okuda et al. ANNALS OF NEUROLOGY
- Associations of sNfL with clinico‐radiological measures in a large MS population
- (2022) Elias S. Sotirchos et al. Annals of Clinical and Translational Neurology
- Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study
- (2021) Ludwig Kappos et al. JAMA Neurology
- Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions
- (2021) Marisa P McGinley et al. LANCET
- 2021 MAGNIMS–CMSC–NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis
- (2021) Mike P Wattjes et al. LANCET NEUROLOGY
- Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis
- (2021) Stephen L Hauser et al. NEUROLOGY
- Therapeutic inertia in relapsing-remitting multiple sclerosis
- (2021) Rita Rodrigues et al. Multiple Sclerosis and Related Disorders
- Determining the effectiveness of early intensive versus escalation approaches for the treatment of relapsing-remitting multiple sclerosis: The DELIVER-MS study protocol
- (2020) Daniel Ontaneda et al. Contemporary Clinical Trials
- Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study
- (2020) Anna He et al. LANCET NEUROLOGY
- Initial high-efficacy disease-modifying therapy in multiple sclerosis: A nationwide cohort study
- (2020) Mathias Due Buron et al. NEUROLOGY
- Ofatumumab versus Teriflunomide in Multiple Sclerosis
- (2020) Stephen L. Hauser et al. NEW ENGLAND JOURNAL OF MEDICINE
- Natalizumab in Multiple Sclerosis Treatment: From Biological Effects to Immune Monitoring
- (2020) Kathy Khoy et al. Frontiers in Immunology
- Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis
- (2019) J. William L. Brown et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Global, regional, and national burden of multiple sclerosis 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016
- (2019) Mitchell T Wallin et al. LANCET NEUROLOGY
- Clinical Outcomes of Escalation vs Early Intensive Disease-Modifying Therapy in Patients With Multiple Sclerosis
- (2019) Katharine Harding et al. JAMA Neurology
- The prevalence of MS in the United States
- (2019) Mitchell T. Wallin et al. NEUROLOGY
- Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis
- (2019) Dalia Rotstein et al. Nature Reviews Neurology
- Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis
- (2019) Daniel Ontaneda et al. LANCET NEUROLOGY
- Optical coherence tomography and multiple sclerosis: Update on clinical application and role in clinical trials
- (2019) Jeffrey Lambe et al. Multiple Sclerosis Journal
- Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial
- (2019) Jeffrey A Cohen et al. LANCET NEUROLOGY
- Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial
- (2019) Giancarlo Comi et al. LANCET NEUROLOGY
- Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study
- (2018) Ludwig Kappos et al. LANCET
- Discontinuation of disease-modifying therapy in patients with multiple sclerosis over age 60
- (2018) Le H Hua et al. Multiple Sclerosis Journal
- ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis
- (2018) Xavier Montalban et al. Multiple Sclerosis Journal
- Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis
- (2018) Alexander Rae-Grant et al. NEUROLOGY
- Oral Therapies for Multiple Sclerosis
- (2018) Simon Faissner et al. Cold Spring Harbor Perspectives in Medicine
- Interferon β for Multiple Sclerosis
- (2018) Dejan Jakimovski et al. Cold Spring Harbor Perspectives in Medicine
- Discontinuation of disease-modifying therapy in patients with multiple sclerosis over age 60
- (2018) Le H Hua et al. Multiple Sclerosis Journal
- ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis
- (2018) Xavier Montalban et al. Multiple Sclerosis Journal
- Therapeutic Inertia in Multiple Sclerosis Care: A Study of Canadian Neurologists
- (2018) Gustavo Saposnik et al. Frontiers in Neurology
- Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
- (2017) Stephen L. Hauser et al. NEW ENGLAND JOURNAL OF MEDICINE
- Meta-analysis of the Age-Dependent Efficacy of Multiple Sclerosis Treatments
- (2017) Ann Marie Weideman et al. Frontiers in Neurology
- Long-term evolution of multiple sclerosis disability in the treatment era
- (2016) et al. ANNALS OF NEUROLOGY
- The state of multiple sclerosis: current insight into the patient/health care provider relationship, treatment challenges, and satisfaction
- (2016) Mar Tintoré et al. Patient Preference and Adherence
- Rituximab and risk of second primary malignancies in patients with non-Hodgkin lymphoma: a systematic review and meta-analysis
- (2015) I. Fleury et al. ANNALS OF ONCOLOGY
- Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond
- (2015) Tobias Ruck et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Aggressive multiple sclerosis: proposed definition and treatment algorithm
- (2015) Carolina A. Rush et al. Nature Reviews Neurology
- Teriflunomide and Its Mechanism of Action in Multiple Sclerosis
- (2014) Amit Bar-Or et al. DRUGS
- Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study
- (2014) Peter A Calabresi et al. LANCET NEUROLOGY
- Significant clinical worsening after natalizumab withdrawal: Predictive factors
- (2014) A Vidal-Jordana et al. Multiple Sclerosis Journal
- The aetiology of acute neurological decline in multiple sclerosis: Experience from an open-access clinic
- (2014) Emma C Tallantyre et al. Multiple Sclerosis Journal
- Moving toward earlier treatment of multiple sclerosis: Findings from a decade of clinical trials and implications for clinical practice
- (2013) Mark S. Freedman et al. Multiple Sclerosis and Related Disorders
- Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
- (2012) Jeffrey A Cohen et al. LANCET
- Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial
- (2012) Alasdair J Coles et al. LANCET
- Scoring treatment response in patients with relapsing multiple sclerosis
- (2012) MP Sormani et al. Multiple Sclerosis Journal
- Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
- (2012) Robert J. Fox et al. NEW ENGLAND JOURNAL OF MEDICINE
- Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
- (2012) Ralf Gold et al. NEW ENGLAND JOURNAL OF MEDICINE
- Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis
- (2011) Paul O'Connor et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis
- (2010) Gavin Giovannoni et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
- (2010) Ludwig Kappos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Measures in the first year of therapy predict the response to interferon β in MS
- (2009) J Río et al. Multiple Sclerosis Journal
- Natural history of secondary-progressive multiple sclerosis
- (2008) Helen Tremlett et al. Multiple Sclerosis Journal
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started